WST Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of --. West Pharmaceutical Services's return on equity of 17.47% beat Perspective Therapeutics's return on equity of --.

West Pharmaceutical Services has a consensus price target of $278.84, signalling upside risk potential of 24.27%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 241.58%. Given that Perspective Therapeutics has higher upside potential than West Pharmaceutical Services, analysts believe Perspective Therapeutics is more attractive than West Pharmaceutical Services.

West Pharmaceutical Services has a beta of 1.088, which suggesting that the stock is 8.813% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.

West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.37%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

West Pharmaceutical Services quarterly revenues are $698M, which are larger than Perspective Therapeutics quarterly revenues of --. West Pharmaceutical Services's net income of $89.8M is higher than Perspective Therapeutics's net income of -$18.2M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 35.22x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.69x versus 29.11x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 12.62%. West Pharmaceutical Services's return on equity of 17.47% beat Globus Medical's return on equity of 4.59%.

West Pharmaceutical Services has a consensus price target of $278.84, signalling upside risk potential of 24.27%. On the other hand Globus Medical has an analysts' consensus of $85.91 which suggests that it could grow by 51.76%. Given that Globus Medical has higher upside potential than West Pharmaceutical Services, analysts believe Globus Medical is more attractive than West Pharmaceutical Services.

West Pharmaceutical Services has a beta of 1.088, which suggesting that the stock is 8.813% more volatile than S&P 500. In comparison Globus Medical has a beta of 1.193, suggesting its more volatile than the S&P 500 by 19.307%.

West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.37%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

West Pharmaceutical Services quarterly revenues are $698M, which are larger than Globus Medical quarterly revenues of $598.1M. West Pharmaceutical Services's net income of $89.8M is higher than Globus Medical's net income of $75.5M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 35.22x while Globus Medical's PE ratio is 42.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.69x versus 3.13x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 6.22%. West Pharmaceutical Services's return on equity of 17.47% beat Insulet's return on equity of 36.9%.

West Pharmaceutical Services has a consensus price target of $278.84, signalling upside risk potential of 24.27%. On the other hand Insulet has an analysts' consensus of $336.85 which suggests that it could grow by 16.85%. Given that West Pharmaceutical Services has higher upside potential than Insulet, analysts believe West Pharmaceutical Services is more attractive than Insulet.

West Pharmaceutical Services has a beta of 1.088, which suggesting that the stock is 8.813% more volatile than S&P 500. In comparison Insulet has a beta of 1.346, suggesting its more volatile than the S&P 500 by 34.619%.

West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.37%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

West Pharmaceutical Services quarterly revenues are $698M, which are larger than Insulet quarterly revenues of $569M. West Pharmaceutical Services's net income of $89.8M is higher than Insulet's net income of $35.4M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 35.22x while Insulet's PE ratio is 51.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.69x versus 9.70x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Treace Medical Concepts has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of -30.29%. West Pharmaceutical Services's return on equity of 17.47% beat Treace Medical Concepts's return on equity of -47.17%.

West Pharmaceutical Services has a consensus price target of $278.84, signalling upside risk potential of 24.27%. On the other hand Treace Medical Concepts has an analysts' consensus of $10.02 which suggests that it could grow by 71.23%. Given that Treace Medical Concepts has higher upside potential than West Pharmaceutical Services, analysts believe Treace Medical Concepts is more attractive than West Pharmaceutical Services.

West Pharmaceutical Services has a beta of 1.088, which suggesting that the stock is 8.813% more volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.37%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

West Pharmaceutical Services quarterly revenues are $698M, which are larger than Treace Medical Concepts quarterly revenues of $52.6M. West Pharmaceutical Services's net income of $89.8M is higher than Treace Medical Concepts's net income of -$15.9M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 35.22x while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.69x versus 1.73x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.